Shandong Xinhua Pharmaceutical's (HKG:0719, SHE:000756) calcium gluconate passed the consistency of quality and efficacy evaluation for generic drugs in China.
The drug is indicated for treating hand-foot weakness caused by calcium deficiency, acute hypocalcemia, allergic diseases, relief from fluorosis, and cardiac resuscitation, among other conditions.
The pharmaceuticals and chemical products company's shares closed over 3% higher on Tuesday.